The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins

British Journal of Clinical Pharmacology

Volumn 45, Issue 2, 1998, Pages 170-172

  Bhathena, R K ^a,c   Anklesaria, B S ^b   Ganatra, A M ^a   Pinto, Rosaline ^a  

^a Menopause Clinic   (India)

^b NHL Municipal Medical College   (India)

^c Petit Parsee General and Masina Hospitals   (India)

Author keywords

Medroxyprogesterone acetate; Serum lipids and lipoproteins; Transdermal oestrogen therapy

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; MEPRATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ADULT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATA INTERPRETATION, STATISTICAL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; PROGESTERONE CONGENERS;

EID: 0031963490     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00658.x     Document Type: Article

References (10)

1. Hirvonen E, Malkonen M, Manninen V. Effects of different progestagens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981; 304: 560-563.
2. The writing group of the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Ass 1995; 273: 199-208.
3. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
4. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994; 62 Suppl 2: 176-179.
5. Wiseman LR, McTavish D. Transdermal estradiol/ norethisterone, - a review of its pharmacological properties and clinical use in postmenopausal women. Drugs & Aging 1994; 4: 238-256.
6. Erenus M, Kutlay K, Kutlay L, Sokak H. Comparison of the impact of oral versus transdermal estrogen on serum lipoproteins. Fertil Steril 1994; 61: 300-302.
7. Stanczyk FZ, Shoupe D, Nunez V, et al. A randomised comparison of non-oral estradiol delivery in postmenopausal women. Am J Obstet Gynaecol 1988; 159: 1540-1546.
8. Whitcroft SI, Crook D, March MS, Ellerington MC, Whitehead MI, Stevenson JC. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynaecol 1994; 84: 222-226.
9. Whitehead MI, Fraser D, Schenkel L, Crook D, Stevenson JC. Transdermal administration of oestrogen/progestagen hormone replacement therapy. Lancet 1990; 335: 310-312.
10. Erkkola RU, Hirvonen EJ, Juntenen KST, et al. Comparison of transdermal to oral hormone replacement therapy, - effects on lipid and carbohydrate metabolism, and on antithrombin III, fibrinogen, renin substrate and sex hormone binding globulin. Eur Menopause J 1995; 2 (Pt 1): 21-27.